Zobrazeno 1 - 10
of 745
pro vyhledávání: '"H. Hausmaninger"'
Autor:
Hubrecht, Georges
Publikováno v:
Latomus, 1967 Apr 01. 26(2), 564-565.
Externí odkaz:
https://www.jstor.org/stable/41525278
Autor:
Boersma, Bart1,2 (AUTHOR) bart.boersma@unige.ch, Poinot, Hélène3,4 (AUTHOR) helene.poinot@unige.ch, Pommier, Aurélien5 (AUTHOR) aurelien.pommier@uca.fr
Publikováno v:
Pharmaceutics. Aug2024, Vol. 16 Issue 8, p974. 31p.
Autor:
Elisabeth Mueller-Holzner, H. Hausmaninger, K. Estermann, Gudrun Windbichler, A. Pelzer, Christian Marth, Edgar Petru
Publikováno v:
International Journal of Gynecological Cancer. 16:1522-1528
We have previously shown that interferon-gamma 1b (IFN-gamma) in combination with cyclophosphamide and cisplatin significantly prolongs progression-free survival in ovarian cancer. In this phase I/II study, we examined if administration of IFN-gamma
Autor:
P. Willemse, C. Ramazeilles, V. Georgoulias, Veronique Cocquyt, Y. Boudraa, H. Hausmaninger, Robert Paridaens, Christoph C. Zielinski, J. Wildiers, F Van Aelst, N. Azli, H. Samonnig
Publikováno v:
Annals of Oncology, 14(3), 433-440. Oxford University Press
Background: This phase II study evaluated the feasibility and efficacy of alternating and sequential regimens of docetaxel and doxorubicin as first-line chemotherapy for metastatic breast cancer (MBC).Patients and methods: Women with MBC requiring fi
Autor:
Ernst Kubista, H. Samonigg, Angelika Reiner, Elisabeth Kucera, Michael Gnant, Martina Mittlböck, Michael Seifert, M. Fridrik, Raimund Jakesz, P. Speiser, H. Hausmaninger, L. Szabo, Robert Zeillinger
Publikováno v:
European Journal of Cancer. 35:398-405
The aim of our study was to evaluate if p53 mutations, especially those in the L2/L3 domains of the p53 gene, add prognostic information for node-positive and steroid receptor positive breast cancer patients. Two hundred and five tumour samples from
Autor:
R. Jakesz, H. Samonigg, M. Gnant, E. Kubista, P. Steindorfer, H. Hausmaninger, P. Sevelda, B. Tschurtschenthaler, M. Fridrik, M. Stierer, R. Kolb, G. Steger, null the Austrian Breast Cancer Study Group
Publikováno v:
European Journal of Cancer. 34:66-70
A randomised clinical trial was performed to test whether or not low-dose chemotherapy lasting only 35 days improves the outcome of breast cancer patients with stage I disease and negative oestrogen and progesterone receptors (ER-, PgR-). Between 198
Autor:
S. Oroszy, W. Oberaigner, Erin L. Schenk, C Peschel, K. Aigner, H Huber, F Kummer, C. Prior, H Hausmaninger
Publikováno v:
European Respiratory Journal. 10:392-396
Preliminary studies have shown bioactivity of interferons (IFNs) in the treatment of small-cell lung cancer (SCLC). The aim of the present study was to determine whether, in patients with advanced SCLC, a combination of recombinant IFN-alpha-2c and s
Autor:
M. A. Fridrik, R. Greil, H. Hausmaninger, O. Krieger, P. Oppitz, M. Stöger, J. Klocker, M. Neubauer, W. Helm, J. Pont, B. Fazeny, M. Hudec, I. Simonitsch, T. Radaszkiewicz
Publikováno v:
Annals of Hematology. 93:539-540
Autor:
H. Hausmaninger
Publikováno v:
European Surgery. 23:230-234
Trotz umfangreicher klinischer Untersuchungen konnte in den letzten 20 Jahren die medikamentose Palliativtherapie fortgeschrittener kolorektaler Karzinome nicht entscheidend verbessert werden. Als Standardtherapie galt bisher eine Monotherapie mit 5-
Autor:
H. Hausmaninger
Publikováno v:
European Surgery. 23:70-75
Durch konventionelle Chemotherapieregime konnen bei Patientinnen mit metastasierendem Mammakarzinom in 40 bis 70% der Falle objektive Tumorruckbildungen erreicht werden, allerdings bei nur 10 bis 20% der behandelten Patientinnen in Form einer komplet